University of Southern California

Biomarin Pharmaceutical Inc.

Ascensia Diabetes Care Holdings Ag

Bayer Healthcare LLC

Lin Chen

Steven C Charlton

Qiang Fu

Igor Y Gofman

Nicos A Petasis

Hoi-Cheong Steve Sun

Paul M Ripley

Jun Chen

Harris Lieber

Dan J Wendt

Steven Brian Harris

Paul Andrew Fitzpatrick

Derek Lok

Tony Nguyen

Minmin Qin

Paul L Inman

Emil D Kakkis

Raymond L Yao

Christopher M Starr

Gregory Stefkovic

Qiong Li

Gary J Johnson

Aidong Han

Nimanthi Jayathilaka

Wai-Pan Chan

Gary N Zecherle

John M Henstrand

Gary Johnson

John M Hendstrand

Stuart Sweidler

Reza Kalhor

Paul A Fitzpatrick

Stuart Swiedler

Hoi-Wah Lok

Disclosed are methods and systems for determining the three-dimensional structure of chromatin in eukaryotic cells. More specifically, disclosed are methods and systems for obtaining chromatin structural information by surface immobilization that includes tethering crosslinked protein:DNA complexes and/or ligated DNA complexes to media such as beads, gels, and or matrices during the conformation capture assay. In general, the method includes flash freezing a cell such that the structural organization of the chromatin or other protein:DNA complexes is preserved, cryomilling the cell, producing cross-linked protein:DNA complexes by cutting the chromatin using a chemical, physical or enzymatic method, substantially immobilizing the cross-linked protein:DNA complexes, ligating the cross-linked protein:DNA complexes intramolecularly such that the ligated protein:DNA complexes represent structural organization of the chromatin; characterizing the ligated DNA by sequencing or other methods; and identifying any structural organization of the chromatin. The structural organization preferably includes information relating to interacting loci of the chromatin.

Genome-wide mapping of DNA-DNA proximities in the nucleus

An architecture allows individual system components to be developed and tested individually, i.e., as distinct modules, and to be subsequently combined through standardized electrical and communication interfaces. Any combination of these modules can be implemented to form different products that provide any number of functions, such as an integrated system for monitoring a health condition and/or delivering a medication. The architecture also provides an approach for dynamically updating the product and offering its users the latest generation of technology even after the users have already purchased the product. In particular, the embodiments employ the communication interfaces to also provide connection to a remote network that can update or upgrade the product's software when the product is out in the field.

Architecture for field upgrade of a health monitoring system

Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.

Small molecules modulator of epigenetic regulation and their therapeutic applications

The invention relates to the use of GCC (Genome Conformation Capture) technology in determining the three dimensional arrangement of an entire genome.

Genome-wide chromosome conformation capture

The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.

Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

The present invention provides a recombinant human &agr;-L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human &agr;-L-iduronidase enzyme as well as methods to treat certain genetic disorders including &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).

Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof

Growing community of inventors

Hopewell Junction, NY, United States of America

Lin Chen